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Abstract 
Background and purpose 
Adjuvant lymphatic radiotherapy (LNRT) is recommended for selected axillary node 
positive women with early breast cancer. We investigated whether hypofractionated 
LNRT is safe combined with similarly-hypofractionated breast/chest wall 
radiotherapy (RT). 
Material and methods 
The Standardisation of Breast Radiotherapy (START) pilot, A and B trials 
randomised women with early breast cancer to schedules of 2.67 Gy - 3.3 Gy versus 
2.0 Gy fractions (control). RT adverse effects were assessed by patients using the 
EORTC QLQ-BR23 and protocol-specific questions, and by physicians. Rates of 
arm/shoulder effects were compared between schedules for patients given LNRT. 
Results 
864/5861 (14.7%) patients received LNRT (385 START-pilot, 318 START-A, 161 
START-B). Prevalences of moderate/marked arm/shoulder effects were low up to 10 
years. There were no significant differences between the hypofractionated and 
control groups for patient- and physician-assessed symptoms in START-A or 
START-B. In START-pilot, adverse effect rates were higher after 13 fractions of 3.3 
Gy, consistent with effects reported in the breast/chest wall (significant for shoulder 
stiffness, HR 3.07, 95%CI 1.62-5.83, p=0.001).  
Conclusions 
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The START trial results suggest that appropriately-dosed hypofractionated LNRT is 
safe in the long-term, according to patient and physician-assessed arm and shoulder 
symptoms. These findings are consistent with those reported after the same 
schedules delivered to the breast/chest wall. 
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Introduction 
Four randomised trials enrolling more than 7000 women with early breast cancer in 
the UK and Canada between 1986 and 2002 have demonstrated that 
hypofractionated radiotherapy (RT) schedules are as effective and safe as standard 
fractionation [1-5]. The three START trials [2-5] tested fraction sizes >2 Gy delivered 
in 3 or 5 weeks against the international standard 50 Gy in 25 fractions over 5 weeks 
and showed non-inferiority for the hypofractionated schedules in terms of local 
tumour control as well as less toxicity relating to late normal tissue effects in the 
breast. Similarly, the Canadian trial [1] showed that 42.5 Gy in 16 fractions delivered 
over 3 weeks was non-inferior to the international standard schedule, although all 
women were axillary node negative and no lymphatic RT was given.  
The results of these trials have been interpreted with various levels of caution in 
different countries. The 2016 consensus statements prepared by the UK Royal 
College of Radiologists states “There is no indication to use more than 15 fractions 
for the breast, chest wall or nodal areas for standard adjuvant treatment.” [6] A more 
restrictive adoption of hypofractionation is indicated in the 2011 American Society for 
Radiation Oncology (ASTRO) guidelines [7], which supported hypofractionated RT in 
selected patients but judged that there were insufficient numbers treated with 
irradiation of nodal areas in the randomised trials to form the basis for an evidence-
based recommendation of hypofractionated lymphatic RT. Similar indications are 
given in guidelines from the German Society of Radiation Oncology (DEGRO) [8], 
the Italian Society of Radiation Oncology (AIRO) [9] and Cancer Australia [10]. 
Using a retrospective evaluation of prospectively collected data from three 
randomised trials, this paper aims to investigate patient- and physician-assessed late 
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normal tissue effects in the arm and shoulder in women treated with lymphatic 
irradiation within the START trials testing hypofractionation in early stage breast 
cancer [2-5], to determine if, as was found in the studies overall, appropriately-dosed 
hypofractionated RT is safe when applied to lymphatic areas.  
 
Materials and Methods 
The START-pilot trial (n=1410, 1986-1998) was a phase III randomised trial in early 
breast cancer (T1-2, N0-1, M0) testing whether fewer larger fractions of post-surgical 
radiotherapy would be as safe and effective as the international standard schedule 
50 Gy in 25 fractions of 2.0 Gy, and tested two hypofractionated schedules (42.9 Gy 
in 13 fractions of 3.3 Gy and 39 Gy in 13 fractions of 3.0 Gy, all given over 5 weeks) 
against this control [2]. Based on this trial, the START trials (1999-2002) were 
initiated consisting of two parallel trials: START-A (n=2236) and START-B (n=2215) 
to extend the testing of radiotherapy schedules using fraction sizes larger than 2.0 
Gy in terms of locoregional tumour control, normal tissue effects, quality of life and 
health economic consequences in early breast cancer (T1-3, N0-1, M0) [3-5]. 
Patients were ineligible for trial entry if they required axillary radiotherapy after 
greater than a Level 1 axillary dissection or after >10 lymph nodes had been 
removed. START-A randomised between 50 Gy in 25 fractions of 2.0 Gy (control), 
41.6 Gy in 13 fractions of 3.2 Gy and 39 Gy in 13 fractions of 3.0 Gy, all given over 5 
weeks. START-B randomised between the same control schedule and 40 Gy in 15 
fractions of 2.67 Gy over 3 weeks. A subset of centres in START-A and START-B 
participated in a quality of life patient-reported outcome measures (PROMS) study, 
which recruited 2208 women who had received breast conserving surgery [11].  
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In all three START trials lymphatic radiotherapy was permitted to the axillary chain 
and/or the supraclavicular nodes; the decision to give lymphatic radiotherapy was 
made before randomisation. Where lymphatic radiotherapy was recommended as 
part of standard of care, most commonly a minimum of 4 positive axillary nodes 
following axillary sampling or dissection, the planning target volume was 
supraclavicular nodes or axillary chain with a 1 cm margin. In two START-A patients 
prescribed radiotherapy to the breast and supraclavicular fossa and randomised to 
the 41·6 Gy schedule, the total dose administered to the supraclavicular fossa was 
reduced to 39 Gy because of a perceived concern about the sensitivity of brachial 
plexus to fraction size. Radiotherapy quality assurance was an integral part of the 
trials. Full details of procedures are described elsewhere [3,4]. 
Late normal tissue effects in the arm and shoulder were assessed by physicians in 
all three trials and also by patients in START-A and START-B. Annual physician 
assessments of late normal tissue effects included shoulder stiffness and arm 
oedema, with the contralateral side used for comparison. In START-A and B, patient-
reported assessments of late normal tissue effects in the arm and shoulder were 
collected using items from the EORTC QLQ-BR23 [12] and protocol-specific 
questions relating to post-radiotherapy changes. Patients completed the EORTC 
QLQ-BR23 at baseline, 6, 12, 24 and 60 months after randomisation; the protocol 
items relating to post-radiotherapy changes were collected at 6, 12, 24 and 60 
months. All physician and patient-reported assessments of late normal tissue effects 
were scored on a 4-point scale (none, a little, quite a bit, very much). Brachial 
plexopathy was reported if damage to the brachial plexus was suspected and the 
patient had symptoms of pain, parasthesia, numbness, or other sensory symptoms 
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(graded on a 4-point scale). Suspected cases of brachial plexopathy were subject to 
confirmation by neurophysiological assessment and MRI. 
The START trials are registered as an International Standard Randomised 
Controlled Trial, number ISRCTN59368779. 
Statistical Methods 
All normal tissue effect assessment scores (patients and physicians) were 
dichotomised as “none/a little” versus “quite a bit/very much” (interpreted as 
none/mild versus moderate/marked effects).  
Survival analysis methods were used to investigate time to first moderate or marked 
effect, using the date of completion of the PROMS questionnaire or date of annual 
follow-up visit to calculate length of follow-up from randomisation. Kaplan-Meier 
estimates of cumulative incidence rates of moderate/marked effects for each 
fractionation schedule were obtained (with 95% confidence intervals, CI). Hazard 
ratios (HR, with 95%CI) for each test schedule compared with the control group were 
obtained from Cox proportional hazards regression analysis using all available 
follow-up data. For symptoms included in the baseline PROMS questionnaire, the 
Cox’s proportional hazards regression model included a term for the baseline score. 
The proportional hazards assumption was checked using Schoenfield residuals.  
As events reported at earlier follow-up may potentially be post-surgical rather than 
radiotherapy effects, cross-sectional analyses were also done, focussing on the point 
prevalence of moderate/marked effects at 5 years (with exact 95% confidence 
interval, CI), and each test schedule compared with the control group using chi-
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squared or Fisher’s exact test where appropriate. Ten-year cross-sectional analyses 
were also done for the physician assessments.  
Corresponding survival analyses for arm and shoulder effects in patients who 
received only breast/chest wall radiotherapy in the START trials were included in 
forest plots for comparison with the lymphatic radiotherapy group.  
Each trial was analysed separately, but no subgroup analyses were done due to the 
small number of patients and events in some groups. There was no formal 
adjustment for multiple testing. 
Analysis was on an intention-to-treat basis, as compliance with the randomised 
treatment was high in the trials. 
 
Results 
Overall 864/5861 (14.7%) patients across all three trials were treated with lymphatic 
radiotherapy and included in this analysis. This includes 385/1410 (27.3%) in the 
START-pilot trial, 318/2236 (14.2%) in START-A and 161/2215 (7.3%) in START-B. 
Of these, physician assessments of normal tissue effects were available for 298/385 
(77.4%) in the pilot trial, 304/318 (95.6%) in START-A and 154/161 (95.6%) in 
START-B. Patient-reported assessments of normal tissue effects were available for 
250/262 (95.4%) patients in START-A who received lymphatic radiotherapy and 
similarly for 98/103 (95.1%) in START-B. Median follow-up for the patients included 
in the analysis was 10 years. 
There were differences between patient characteristics of those who received 
lymphatic radiotherapy in the three trials (Table 1). The majority of patients in the 
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START-pilot trial received RT to both the axilla and SCF (75.0%), compared with 
9.2% in START-A and 13.0% in START-B. Lymphatic RT to the axilla only was 
received by 0.3% in each of the START-pilot and START-A trials and 29.8% in 
START-B, and by 24.7%, 90.5% and 57.2% to SCF only in the START-pilot, A and B 
trials respectively.  More patients received axillary surgery in START-A (97.2%) and 
START-B (95.1%) than in the START-pilot trial (39.6%). Patients were only eligible 
for the START-pilot trial following breast conserving surgery; START-A and B 
included mastectomy, with more in START-A (46.2%) compared with START-B 
(34.2%). Tumour grade was not available for all patients (particularly in the START-
pilot trial), but tended to be lower for patients in START-B (112 grade 1 or 2 out of 
158, 70.9%) compared with 51.5% (34/66) in the START-pilot and 58.4% (184/315) 
in START-A out of those for whom grade was known. Adjuvant therapies also varied, 
with 37.7% in the START-pilot trial receiving tamoxifen only, compared with 18.6% in 
START-A and 41.6% in START-B, and more patients receiving chemotherapy in trial 
A compared with trial B. Fewer patients in START-B received a breast radiotherapy 
boost (51.9%) compared with 73.8% in the pilot and 83% in START-A.  
Survival analyses 
Cumulative incidence rates of patient-assessed moderate/marked effects in the arm 
or shoulder up to 5 years were similar between the test and control schedules in 
START-A and START-B (Table 2). The number of cumulative events per schedule 
was small for many of the outcomes, reflected in the wide CIs. In the 50 Gy control 
groups, rates were highest for arm/shoulder pain (32.3%, 95%CI 23.3-43.7 by 5 
years in START-A) and lowest for arm/hand swelling (9.5%, 95%CI 3.7-23.3 by 5 
years in START-B). None of the hazard ratios indicated a statistically significant 
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difference in patient-assessed arm or shoulder effects between the hypofractionated 
schedules and the 50 Gy control groups for either START-A or START-B.  
For physician-assessed moderate/marked arm oedema or shoulder stiffness, 
cumulative incidence rates up to 5 and 10 years were generally similar between the 
test and control schedules in the START-pilot, START-A and START-B trials, with 
few events reported in most categories (Table 3). There was a statistically significant 
increased rate of physician-assessed shoulder stiffness in the 42.9 Gy schedule 
compared with 50 Gy in START-pilot (HR 3.07, 95%CI 1.62-5.83, p=0.001) but no 
such effect for the hypofractionated schedules in START-A and START-B. There 
were no statistically significant differences in physician-assessed moderate/marked 
arm oedema between the schedules for any of the trials. There was generally little 
increase in effects over time, with 5- and 10-year cumulative incidence rates for 
physician-assessed arm oedema and shoulder stiffness broadly similar.   
Using the patients in the START trials who only received breast/chest wall RT as a 
comparison group, there was no evidence of a statistical difference in hazard ratios 
for the hypofractionated schedules compared with 50 Gy according to whether or not 
lymphatic RT was given (results for arm oedema and shoulder stiffness are shown in 
Figures 1 and 2 for patient and physician assessments respectively).  
Cross-sectional analyses 
At 5 years following radiotherapy, the point prevalences of moderate/marked effects 
in the arm or shoulder reported by patients and physicians were low overall, with 
very few events and no statistically significant differences between the 
hypofractionated and control schedules for any of the trials (Tables 2 and 3). This 
remained so for the physician assessments at 10 years (Table 3). The 5- and 10-
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year point prevalences were much lower than the estimates of cumulative incidence 
up to 5 and 10 years for all of the effects.   
 
Discussion 
Our investigation of late normal tissue effects in the arm and shoulder for women 
treated with locoregional RT within the START trials suggests that appropriately-
dosed hypofractionated lymphatic irradiation is comparable to the traditional 
normofractionated (2.0 Gy) schedule in terms of safety. Adverse event rates were 
low overall, and point prevalences at 5 and 10 years were generally considerably 
lower than cumulative incidence rates, partly due to reversal of post-surgical effects 
reported early in follow-up. Although we have not carried out formal tests of 
interaction due to small sample sizes in subgroups, comparing results of relative 
treatment effects between patients with and without lymphatic RT in the START trials 
showed no evidence of differential effects of the hypofractionated schedules 
compared with the control schedule of 50 Gy in 25 fractions, supporting our 
conclusions. This is an important point, since it suggests that arm oedema and 
shoulder stiffness are no more sensitive to fraction size than breast/chest wall 
toxicity endpoints. Thus, the higher hazard ratios for arm oedema and shoulder 
stiffness reported in the START-pilot trial after 13 fractions of 3.3 Gy compared with 
50 Gy in 25 fractions are not surprising given that this test dose level is equivalent to 
prescribing 54 Gy in 2.0 Gy fractions, assuming an alpha/beta ratio of 3 Gy. 
A comparison of these results with published data is not straightforward as various 
studies define and measure arm and shoulder normal tissue effects in distinct ways 
and at different time points. Evaluation method and time interval from treatment have 
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an impact on arm oedema scores, as reported in a systematic review of the evidence 
related to lymphedema in breast cancer patients [13]. In the review, clinical diagnosis 
by physicians resulted in 12.6% incidence of lymphoedema compared with self-
reported swelling in 20.4%. In the EORTC 10981-22023 AMAROS trial testing 
radiotherapy versus surgery of the axilla after a positive sentinel node biopsy, 
lymphoedema was reported less often when defined as an increase in arm 
circumference of ≥10% (6% rate at 5 years) compared with clinician evaluation 
based on presence of ‘any’ signs of arm oedema (11% rate at 5 years) [14]. The 
systematic review and the AMAROS trial both suggested that incidence of arm 
oedema tended to increase in the first 1 or 2 years following diagnosis or surgery, 
and then to decrease [13,14]. It is reassuring that the START data show no relative 
differences between the schedules, however it is likely that absolute rates of normal 
tissue effects are now lower using modern target volume-based RT compared with 
the field-based RT used in the era of the START trials.  
In the START trials radiotherapy-related adverse effects in the arm and shoulder 
were assessed using both patient and physician assessments, each based on a 4-
point scale. Although patients report higher absolute event rates than physicians, as 
previously described for breast adverse effects [15], the overall conclusions from the 
comparison of schedules are consistent, strengthening the conclusions from this 
retrospective analysis that there is no evidence of a detrimental effect of the 
hypofractionated schedules on arm and shoulder symptoms. The importance of the 
PROMS is re-enforced by data suggesting a correlation between functional 
symptoms, including shoulder stiffness and arm/shoulder pain, and quality of life 
indices in women treated with conservative surgery and radiotherapy for breast 
cancer [16]. In our study, the 5- and 10-year prevalence data from physician 
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assessments show that lymphoedema rates are relatively stable at these time points, 
suggesting the safety of hypofractionated lymphatic radiotherapy in the long-term.   
Due to differences between the START-pilot, A and B trials, the patient sample 
included in this retrospective analysis is heterogeneous in terms of proposed risk 
factors for arm and shoulder toxicity, i.e. axillary treatment, extent of surgery, 
adjuvant systemic therapy and radiotherapy technique. This variation does not 
impact on the comparative analysis between normofractionated and 
hypofractionated schedules however, as these variables are well-balanced amongst 
randomised groups in each trial [2-4]. The main limitation of this retrospective 
analysis is the relatively small sample size of the lymphatic radiotherapy subgroups 
in each trial and the low rates of reported late normal tissue events in the arm and 
shoulder, which limit the statistical power of the analyses. Additionally, due to the low 
locoregional relapse rates in the START trials overall, the number of events 
prohibited reliable statistical analysis of the efficacy of hypofractionated lymphatic 
radiotherapy in terms of tumour control in this subgroup analysis.  
Radiobiological estimates of equivalent total dose in 2.0 Gy fractions (EQD2Gy) for 
the tested hypofractionated schedules with regard to brachial plexus toxicity [17] 
raise no specific concerns with regard to the brachial plexus. Based on the START 
trials, the EQD2Gy of 40 Gy in 15 fractions is 46 Gy and 48 Gy, assuming alpha/beta 
values of 3 Gy and 1.5 Gy, respectively. One patient in the START trials developed 
mild symptoms and signs of brachial plexopathy two years following treatment to the 
breast and supraclavicular fossa on the 41.6 Gy schedule in START-A. She had a 
family history of polydactyly (accessory thumb) on the affected side, raising the 
possibility of a yet-to-be-identified genetic predisposition. Lymphatic radiotherapy is 
now volume-based and doses are prescribed to more relevant reference points [18]. 
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In the START-pilot trial, lymphatic radiotherapy comprising an anterior field to the 
supraclavicular fossa was prescribed as an applied dose. If the axilla was included, 
an equally weighted posterior axillary field was treated with every fraction to ensure 
that 100% of the prescribed dose was delivered to the axillary midline [2]. In the 
START-A and –B trials, a posterior field, weighted according to axillary separation 
was adopted if the mid-axilla dose fell below 80% of the applied dose. A reassuring 
point is that fractionation sensitivity will not change, even though volume coverage, 
dose intensity and homogeneity may do so. If radiation oncologists are confident in 
prescribing 50 Gy in 25 fractions to contemporary lymphatic volumes and reference 
points, the START analysis presented here suggests they can be equally confident 
in prescribing appropriately-dosed hypofractionation.  
 
In order to address residual concerns regarding extensive adoption of moderate 
hypofractionation in women undergoing radiotherapy for breast cancer worldwide, 
five randomised trials have been launched in the last two years in Denmark, US, 
Egypt and France. The largest trial (target N=2000) is sponsored by the Danish 
Breast Cancer Cooperative Group (ClinicalTrials.gov identifier: NCT02384733), 
testing 40 Gy in 15 fractions versus 50 Gy in 25 fractions in terms of late normal 
tissue effects and tumour control in patients treated with mastectomy or breast 
conserving surgery for pT1-3, pN0-3, M0 invasive breast cancer with indications for 
radiotherapy to regional lymph nodes. The other four randomised trials 
(ClinicalTrials.gov identifiers: NCT02690636, NCT02700386, NCT02958774, 
NCT03127995) have a similar design, with the test group receiving 15 or 16 fractions 
of 2.7 Gy and the control group receiving the normofractionated 25 fraction schedule. 
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Internal mammary node irradiation, which was not permitted in the START trials, is 
also being investigated in two of these trials.  
Shorter course hypofractionation for lymphatic radiotherapy is being investigated in a 
sub-study of the UK FAST-Forward randomised trial (ISRCTN19906132), which 
compares two 5-day schedules (27 Gy in 5 fractions of 5.4 Gy and 26 Gy in 5 
fractions of 5.2 Gy) with 40 Gy in 15 fractions over 3 weeks (control).  
Within the next few years, these randomised trials will produce long-term data on 
locoregional tumour control and toxicity in over 3700 women treated with 
hypofractionated lymphatic radiotherapy. In the meantime, whilst bearing in mind the 
statistical limitations, the long-term results from this retrospective subgroup analysis 
of the START trials suggest that appropriately-dosed hypofractionated lymphatic 
radiotherapy is safe, a conclusion consistent with the findings for >2.0 Gy schedules 
delivered to the breast/chest wall. 
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Figure legends 
Figure 1: Patient-assessed arm and shoulder effects according to +/- lymphatic RT 
RT – radiotherapy 
LNRT = lymphnodal radiotherapy 
 
Figure 2: Physician-assessed arm and shoulder effects according to +/- lymphatic 
RT 
RT – radiotherapy 
LNRT = lymphnodal radiotherapy 
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Figure 1:  
 
LNRT = lymphnodal RT 
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Figure 2:  
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Table 1: Baseline and treatment characteristics of patients who received 
lymphatic radiotherapy in the START-pilot, START-A and START-B trials 
 START-pilot 
Total 
n=385 (%) 
 
START-A 
Total 
n=318 (%) 
 
START-B 
Total 
n=161 (%) 
 
Age (years)    
Median (IQR) [range] 
 
52.4 (45.5-60.5) 
[25.4-78.5] 
56.2 (48.7-65.4) 
[25.7-81.9] 
56.6 (50.7-65.2) 
[24.7-86.8] 
Primary Surgery    
Breast Conserving Surgery 385 (100.0) 171 (53.8) 106 (65.8) 
Mastectomy 0 147 (46.2) 55 (34.2) 
Histological type    
Invasive Ductal 297 (77.1) 256 (80.5) 126 (78.3) 
Invasive Lobular 27 (7.0) 42 (13.2) 26 (16.2) 
Mixed Ductal/Lobular 14 (3.7) 10 (3.1) 2 (1.2) 
Other 47 (12.2) 8 (2.5) 6 (3.7) 
Not known 0 2 (0.7) 1 (0.6) 
Pathological Node Status    
Positive 129 (33.5) 274 (86.2) 144 (89.4) 
Negative 21 (5.5)  34 (10.7) 9 (5.6) 
Not known (no axillary surgery) 233 (60.5)  9 (2.8) 8 (5.0) 
Not known (missing data) 2 (0.5) 1 (0.3) 0 
If positive, number of 
involved nodes: 
   
Median (IQR) [range] 2 (1-5) [1-19] 3 (1-6) [1-25] 3 (1-6) [1-23] 
Tumour Size (cm)    
<1 7 (1.8) 12 (3.8) 3 (1.9) 
1- 109 (28.3) 105 (33.0) 49 (30.4) 
2- 106 (27.5) 111 (34.9) 61 (37.9) 
3- 85 (22.1) 86 (27.0) 47 (29.2) 
Not known 78 (20.3) 4 (1.3) 1 (0.6) 
Tumour Grade    
1 8 (2.1) 28 (8.8) 31 (19.3) 
2 26 (6.7) 156 (49.1) 81 (50.3) 
3 32 (8.3) 131 (41.2) 46 (28.6) 
Not known (missing data) 
Not known (Not applicable*) 
319 (82.9) 
0 
0 
3 (0.9) 
1 (0.6) 
2 (1.2) 
Adjuvant Therapy    
None 0 5 (1.6) 4 (2.5) 
Tamoxifen Only 145 (37.7) 59 (18.6) 67 (41.6) 
Chemotherapy Only 19 (4.9) 56 (17.6) 16 (9.9) 
Tamoxifen + chemotherapy 44 (11.4) 184 (57.9) 74 (46.0) 
Other endocrine therapy ** / 
Not known 
177 (46.0) 14 (4.3) 0 
Lymphatic treatment    
Surgery + Axilla Only 1 (0.3) 0 (0.0) 48 (29.8) 
Surgery + SCF Only 93 (24.2) 285 (89.6) 90 (56.0) 
Surgery + Axilla + SCF 58 (15.1) 24 (7.6) 15 (9.3) 
No Surgery + Axilla Only 0 (0.0) 1 (0.3) 0 (0.0) 
No Surgery + SCF Only 2 (0.5) 3 (0.9) 2 (1.2) 
No Surgery + Axilla + SCF 231 (59.9) 5 (1.6) 6 (3.7) 
Boost (BCS patients only)    
Yes 284 (73.8) 142 (83.0) 55 (51.9) 
No 101 (26.2) 26 (15.2) 51 (48.1) 
Not known 0 3 (1.8) 0 
IQR = interquartile range; SCF = supraclavicular fossa; BCS = breast conserving surgery; *Lobular and other histological types; 
**Other endocrine therapies include combinations of tamoxifen / anastrozole / exemestane / goserelin, mostly within 
randomised trials 
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Table 2: Patient-assessed moderate/marked normal tissue effects in the arm or 
shoulder following lymphatic radiotherapy in START-A and START-B 
Schedule Total 
moderate/ 
marked 
events 
(n/total, %) 
Estimated 
cumulative 
incidence by 5 
years, % 
(95%CI) 
Hazard ratio 
(95% CI)
1
 
P-
value
2
 
Prevalence 
of  
moderate/ 
marked 
events at 5 
years, 
n/total (%) 
P-
value
3
 
Arm/shoulder pain 
START-A 
50 Gy 
41.6 Gy 
39 Gy 
 
30/95 (31.6) 
24/78 (30.8) 
23/77 (29.9) 
 
32.3 (23.3-43.7) 
31.4 (22.1-43.6) 
30.8 (21.4-43.0) 
 
1 
1.03 (0.60-1.77) 
0.96 (0.56-1.66) 
 
 
0.92 
0.89 
 
12/65 (18.5) 
5/58 (8.6) 
7/58 (12.1) 
 
 
0.13 
0.45 
START-B 
50 Gy 
40 Gy 
 
13/46 (28.3) 
15/52 (28.9) 
 
29.7 (18.0-46.6) 
23.6 (14.1-37.9) 
 
1 
0.94 (0.44-2.00) 
 
 
0.87 
 
2/28 (7.1) 
4/35 (11.4) 
 
 
0.68 
Swelling in arm or hand 
START-A 
50 Gy 
41.6 Gy 
39 Gy 
 
15/95 (15.8) 
13/78 (16.7) 
13/77 (16.9) 
 
14.2 (8.3-23.8) 
18.2 (11.0-29.3) 
16.1 (9.2-27.3) 
 
1 
1.01 (0.46-2.18) 
1.15 (0.54-2.47) 
 
 
0.99 
0.72 
 
6/65 (9.2) 
1/58 (1.7) 
6/58 (10.3) 
 
 
0.12 
>0.99 
START-B 
50 Gy 
40 Gy 
 
5/46 (10.9) 
3/51 (5.9) 
 
9.5 (3.7-23.3) 
6.0 (2.0-17.4) 
 
1 
0.55 (0.13-2.36) 
 
 
0.42 
 
1/28 (3.6) 
0/36 (0) 
 
 
0.44 
Difficulty in raising arm 
START-A 
50 Gy 
41.6 Gy 
39 Gy 
 
17/95 (17.9) 
9/78 (11.5) 
11/77 (14.3) 
 
18.8 (11.9-29.0) 
9.5 (4.7-19.0) 
15.4 (8.8-26.1) 
 
1 
0.63 (0.28-1.43) 
0.83 (0.39-1.80) 
 
 
0.27 
0.64 
 
3/65 (4.6) 
2/58 (3.4) 
2/58 (3.4) 
 
 
>0.99 
>0.99 
START-B 
50 Gy 
40 Gy 
 
8/46 (17.4) 
7/51 (13.7) 
 
18.6 (9.2-35.4) 
10.1 (4.3-22.6) 
 
1 
0.64 (0.23-1.78) 
 
 
0.40 
 
3/28 (10.7) 
3/36 (8.3) 
 
 
>0.99 
Shoulder stiffness 
START-A 
50 Gy 
41.6 Gy 
39 Gy 
 
25/96 (26.0) 
15/78 (19.2) 
10/77 (13.0) 
 
27.5 (19.0-38.7) 
17.7 (10.6-28.5) 
14.0 (7.8-24.4) 
 
1 
0.75 (0.39-1.43) 
0.52 (0.25-1.11) 
 
 
0.39 
0.09 
 
8/65 (12.3) 
4/58 (6.9) 
2/58 (3.4) 
 
 
0.37 
0.10 
START-B 
50 Gy 
40 Gy 
 
5/46 (10.9) 
7/52 (13.5) 
 
12.0 (5.2-26.5) 
14.2 (7.0-27.6) 
 
1 
0.88 (0.26-2.97) 
 
 
0.83 
 
1/28 (3.6) 
2/36 (5.6) 
 
>0.99 
1 Results adjusted for baseline; P-values represent comparison of each test 
schedule with 50 Gy; 2 Wald test; 3 Fisher’s exact test; 
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Table 3: Physician-assessed moderate/marked normal tissue effects in the arm or shoulder following lymphatic 
radiotherapy in START-pilot, START-A and START-B 
Schedule Total 
moderate/ 
marked 
events 
(n/total, %) 
Estimated 
cumulative 
incidence by 5 
years, % 
(95%CI) 
Estimated 
cumulative 
incidence by 
10 years, % 
(95%CI) 
Hazard ratio 
(95% CI) 
P-
value
1
 
Prevalence of 
moderate/ 
marked 
events at 5 
years, n/total 
(%) 
P-
value
2
 
Prevalence of 
moderate/ 
marked 
events at 10 
years, n/total 
(%) 
P-
value
2
 
Arm oedema 
START-
pilot 
50 Gy 
42.9 Gy 
39 Gy 
 
 
8/102 (7.8) 
14/99 (14.1) 
5/97 (5.2) 
 
 
6.6 (3.0-14.1) 
13.9 (8.1-23.3) 
3.6 (1.2-10.9) 
 
 
8.2 (4.0-16.7) 
17.0 (10.4-27.3) 
3.6 (1.2-10.9) 
 
 
1 
1.95 (0.82-4.66) 
0.63 (0.21-1.93) 
 
 
 
0.13 
0.42 
 
 
0/57 (0) 
2/56 (3.6) 
2/63 (3.2) 
 
 
 
0.24 
>0.99 
 
 
1/36 (2.8) 
2/27 (7.4) 
1/33 (3.0) 
 
 
 
0.57 
0.19 
START-A 
50 Gy 
41.6 Gy 
39 Gy 
 
15/117 (12.8) 
16/95 (16.8) 
6/92 (6.5) 
 
12.8 (7.6-12.2) 
11.9 (6.6-21.0) 
6.4 (14.1-34.7) 
 
16.3 (9.9-26.2) 
22.5 (14.1-34.7) 
8.2 (3.7-17.6) 
 
1 
1.31 (0.65-2.66) 
0.50 (0.20-1.30) 
 
 
0.45 
0.16 
 
2/80 (2.5) 
3/63 (4.8) 
2/61 (3.3) 
 
 
0.65 
>0.99 
 
1/27 (3.7) 
2/32 (6.3) 
2/29 (6.9) 
 
 
>0.99 
>0.99 
START-B 
50 Gy 
40 Gy 
 
7/73 (9.6) 
3/81 (3.7) 
 
6.0 (2.3-15.3) 
2.8 (0.7-10.7) 
 
13.5 (6.4-27.0) 
4.7 (1.5-14.0) 
 
1 
0.42 (0.11-1.63) 
 
 
0.21 
 
0/51 (0) 
2/57 (3.5) 
 
 
0.50 
 
0/27 (0) 
0/20 (0) 
 
 
- 
Shoulder stiffness 
START-
pilot 
50 Gy 
42.9 Gy 
39 Gy 
 
 
13/102 (12.8) 
34/99 (34.3) 
14/97 (14.4) 
 
 
12.3 (7.2-20.7) 
33.4 (24.7-44.1) 
11.9 (6.8-20.6) 
 
 
13.7 (8.2-22.6) 
36.6 (27.3-47.7) 
14.9 (8.9-24.5) 
 
 
1 
3.07 (1.62-5.83) 
1.09 (0.51-2.31) 
 
 
 
0.001 
0.83 
 
 
1/57 (1.8) 
1/56 (1.8) 
5/63 (7.9) 
 
 
 
0.50 
0.21 
 
 
0/35 (0) 
2/27 (7.4) 
1/33 (3.0) 
 
 
 
>0.99 
0.48 
START-A 
50 Gy 
41.6 Gy 
39 Gy 
 
14/117 (12.0) 
10/95 (10.5) 
8/92 (8.7) 
 
8.8 (4.7-16.4) 
7.1 (3.3-15.2) 
7.5 (3.4-16.0) 
 
17.5 (10.2-29.1) 
14.8 (8.0-26.6) 
11.0 (5.6-21.0) 
 
1 
0.85 (0.38-1.91) 
0.74 (0.31-1.76) 
 
 
0.69 
0.49 
 
1/80 (1.3) 
0/63 (0) 
0/61 (0) 
 
 
>0.99 
>0.99 
 
1/27 (3.7) 
0/32 (0) 
0/29 (0) 
 
 
0.46 
0.48 
START-B 
50 Gy 
40 Gy 
 
4/73 (5.5) 
3/81 (3.7) 
 
2.9 (0.7-11.0) 
3.1 (0.8-11.9) 
 
8.2 (2.9-21.8) 
3.1 (0.8-11.9) 
 
1 
0.76 (0.17-3.39) 
 
 
0.72 
 
1/51 (2.0) 
1/57 (1.8) 
 
>0.99 
>0.99 
 
1/27 (3.7) 
1/20 (5.0) 
 
>0.99 
>0.99 
P-values represent comparison of each test schedule with 50 Gy; 1 Wald test; 2 Fisher’s exact test 
